DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Persistent Lyme Empiric Antibiotic Study Europe

Information source: Radboud University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Lyme Disease; Borrelia Infection

Intervention: Doxycycline (Drug); Clarithromycin and hydroxychloroquine (Drug); Placebo (Drug)

Phase: Phase 4

Status: Active, not recruiting

Sponsored by: Radboud University

Official(s) and/or principal investigator(s):
Bart-Jan Kullberg, Prof., M.D., Principal Investigator, Affiliation: Radboud University

Summary

The purpose of the study is to establish whether prolonged antibiotic treatment of patients diagnosed with proven or presumed PLD (as endorsed by the international ILADS guidelines) leads to better patient outcome than short-term treatment as endorsed by the Dutch CBO guidelines.

Clinical Details

Official title: Persistent Lyme Empiric Antibiotic Study Europe. A Prospective, Randomised Study Comparing Two Prolonged Oral Antibiotic Strategies After Initial Intravenous Ceftriaxone Therapy for Patients With Symptoms of Proven or Possible Persistent Lyme Disease

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Global score 36-item Short-form General Health Survey (SF 36)

Secondary outcome:

Subscales 36-item Short-form General Health Survey (SF 36)

Actometer recording during 14 days (objective physical activity)

Measurements of neuropsychological impairment

Economic evaluation: Questionaire EQ-5D, health consumption and productivity of labour

Fatigue subscale of Checklist Individual Strength (CIS)

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Males or non-pregnant, non-lactating females who are 18 years or older.

- Women of child-bearing potential must agree to use contraception methods other than

oral contraceptives during the study therapy period, since failure of oral contraceptives due to long-term antibiotic use has been described and doxycycline might be teratogenic.

- Patients with presumed or proven PLD. In this study, clinical suspicion of PLD is

defined as complaints of musculoskeletal pain, arthritis or arthralgia, neuralgia or sensory disturbances (such as paresthesias or dysesthesias), neuropsychological or cognitive disorders, and persistent fatigue, that are:

- temporally related to an episode of erythema migrans or otherwise proven

symptomatic Lyme disease (defined as within 4 months after erythema migrans as assessed by a physician, or positive biopsy, PCR, culture, intrathecal B. burgdorferi antibodies), OR

- accompanied by a positive B. burgdorferi IgG or IgM immunoblot (as defined by

strict criteria in line with the European Union Concerted Action on Lyme Borreliosis (EUCALB)), regardless of prior ELISA IgG/IgM screening results.

- Subjects must sign a written informed consent form.

Exclusion Criteria:

- Subjects with a known history of allergy or intolerance to tetracyclines, macrolides,

hydroxychloroquine or ceftriaxone.

- Subjects who have had more than 5 days of antimicrobial therapy with activity against

B. burgdorferi within the previous 4 weeks.

- Subjects with a presumed diagnosis of neuroborreliosis (CSF pleocytosis or

intrathecal antibody production) for which intravenous antimicrobial therapy is required.

- Subjects with a known diagnosis of HIV-seropositivity or other immune disorders. (No

HIV serologic testing is required for the study).

- Subjects with positive syphilis serology or signs of other spirochetal diseases.

- Subjects with moderate or severe liver disease defined as alkaline phosphatase, ALAT,

or ASAT greater than 3 times upper limit of normal.

- Subjects who are receiving and cannot discontinue cisapride, astemizole, terfenadine,

barbiturates, phenytoin, or carbamazepine (The concentrations of these drugs may increase during clarithromycin therapy and/or lead to reduced availability of doxycycline).

- Subjects who are currently enrolled on other investigational drug trials or receiving

investigational agents.

- Subjects who have been previously randomized into this study.

- Severe physical or psychiatric co-morbidity that interferes with participation in the

study protocol, including previous medical diagnosis of rheumatic conditions, chronic fatigue syndrome or chronic pain conditions as well as insufficient command of the Dutch language.

- Co-morbidity that could (partially) account for the symptoms of the subject (e. g.

vitamin B12 deficiency, anemia, hypothyroidism).

Locations and Contacts

Radboud University Nijmegen Medical Centre, Nijmegen 6500 HB, Netherlands

Sint Maartenskliniek, Nijmegen 6522 JV, Netherlands

Additional Information

Starting date: September 2010
Last updated: June 10, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017